Sotera Health (NASDAQ:SHC) Posts Earnings Results, Beats Estimates By $0.04 EPS

Sotera Health (NASDAQ:SHC) released its quarterly earnings results on Monday. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.04, Briefing.com reports. Sotera Health had a net margin of 5.09% and a return on equity of 48.47%. The business had revenue of $277.00 million for the quarter, compared to analysts’ expectations of $266.45 million. During the same quarter in the previous year, the business posted $0.19 earnings per share. The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. Sotera Health updated its FY24 guidance to $0.67-$0.75 EPS and its FY 2024 guidance to 0.670-0.750 EPS.

Sotera Health Stock Performance

NASDAQ:SHC traded down $0.39 during mid-day trading on Wednesday, reaching $14.31. The company’s stock had a trading volume of 1,116,702 shares, compared to its average volume of 1,341,121. The firm’s fifty day moving average price is $12.33 and its two-hundred day moving average price is $12.84. The company has a current ratio of 3.20, a quick ratio of 2.86 and a debt-to-equity ratio of 5.39. The stock has a market cap of $4.05 billion, a P/E ratio of 77.37 and a beta of 2.06. Sotera Health has a 12-month low of $10.71 and a 12-month high of $17.44.

Analyst Ratings Changes

SHC has been the topic of several research reports. Barclays lifted their price objective on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday. Royal Bank of Canada reissued an “outperform” rating and set a $17.00 price objective on shares of Sotera Health in a research report on Tuesday. Finally, Piper Sandler initiated coverage on shares of Sotera Health in a research report on Tuesday, May 21st. They issued a “neutral” rating and a $13.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Sotera Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.70.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.